Table 5.
Cox survival analysis of predictors of overall accumulative survival in 316 hepatocelluar carcinom patients after radiofrequency ablation
| Characteristic |
Univariate |
Multivariate |
||||
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Sex | 1.149 | 0.709-1.862 | 0.572 | |||
| Age | 0.754 | 0.506-1.125 | 0.166 | |||
| Pathology grade | 2.509 | 1.593-3.952 | < 0.001 | |||
| Etiology of cirrhosis | 0.862 | 0.720-1.031 | 0.105 | |||
| Portal vein hypertension | 2.686 | 1.826-3.951 | < 0.001 | 2.743 | 1.462-5.149 | 0.002 |
| Liver function enzyme (AST/ALT) | 1.162 | 0.758-1.780 | 0.491 | |||
| Child-Pugh classification | 3.210 | 2.297-4.488 | < 0.001 | 4.054 | 2.346-7.005 | < 0.001 |
| Serum AFP | 1.501 | 1.021-2.206 | 0.039 | |||
| CEUS pre-RFA | 0.438 | 0.295-0.651 | < 0.001 | |||
| Number of tumor | 2.293 | 1.518-3.463 | < 0.001 | 2.693 | 1.399-5.185 | 0.003 |
| Tumor size | 1.318 | 0.879-1.978 | 0.181 | |||
| Risky location | 1.090 | 0.735-1.616 | 0.670 | |||
| Type of RFA electrodes | 0.191 | 0.077-0.473 | < 0.001 | |||
| Primary technical success | 2.592 | 1.269-5.296 | 0.009 | |||
| Number of RFA sessions | 0.955 | 0.703-1.298 | 0.769 | |||
HCC: Hepatocelluar carcinoma; HR: Hazard ratio; AFP: Alpha–fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CEUS: Contrast enhanced ultrasound; RFA: Radiofrequency ablation.